NCT05727644View on ClinicalTrials.gov

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

November 10, 2023

Study Completion Date

November 10, 2023

Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
DRUG

NNC0194-0499

Participants will receive a single subcutaneous injection of 30 mg NNC0194-0499.

Trial Locations (1)

10117

Novo Nordisk Investigational Site, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY